American AI Drones Racing Against China Take Off: Anduril’s ‘Fury’ Flies Solo as US Air Force Eyes Mass Production

Anduril’s “Fury” unmanned jet just made its maiden voyage, and Wall Street brokers may want to add aviation-grade sunglasses to their trading arsenals—the future is flying right past their window, pilot-optional and powered by lines of code less prone to turbulence than the average hedge fund manager on earnings day. Semi-autonomous is the new sexy, at least according to the defense-tech startup Anduril, whose battle-ready brainchild, the YFQ-44A, took to California skies in late October, prepping to join the U.S. Air Force’s Collaborative Combat Aircraft (CCA) program faster than you can say “recurring revenue.”

Jet-Powered Disruption

Fury’s defining charm isn’t just its lack of cockpit or pilot but its software-driven independence. The drone isn’t piloted remotely; it executes pre-set mission plans while briskly updating its altitude, navigation, and throttle—all by itself and all under strictly supervised ground command. To placate any generals with flashbacks of rogue bots, Fury includes a kill switch for immediate mission abort and reserves lethal action (think: missile launches) for explicit human approval—ensuring that digital ethics remain more than a line item on a press release.

Mass Production with American Flair

In a plot twist worthy of Silicon Valley, Anduril’s engineers cut down old-school defense bottlenecks, opting for mass-producible commercial business jet engines and machine shop-friendly landing gear. The secret sauce? Designing every component for rapid U.S. manufacture, allowing Fury jets to be churned out nationwide—potentially at bargain-bin prices compared to traditional fighters, and with supply chain resilience likely to make procurement officers weep tears of joy.

Wingmen Wanted: The Broader CCA Race

Notably, Anduril isn’t jetting solo into the combat drone sector. General Atomics, pride of the MQ-9 Reaper, recently staged its own test flight for the YFQ-42A, making this competition more “Top Gun” than “WarGames.” But don’t expect Anduril’s CEO Palmer Luckey to get sidetracked; he’s racing against China, not just other San Diego startups. Air Force press releases trumpet a new era where robotic aircraft don’t just outperform in a test vacuum—they collaborate directly with manned F-35s, acting as forward scouts, deadly sentinels, or highly obedient flying interns depending on the threat landscape.

AI Morality: Smarter Than Your Average Landmine

Thanks to built-in autonomy and strict human-in-the-loop safeguards, the system reflects a weirdly reassuring ethical stance: smarter weapons are less likely to confuse a school bus for enemy armor. In a philosophical flourish, Luckey muses that the real horror isn’t thinking machines, but dumb ones. So, rest easy, global citizens—the tech arms race is tilting toward drones with enough intelligence to know when not to autodeploy the fireworks.

Closing Thoughts

As investors and defense wonks speculate on Anduril’s next move (mass production, or perhaps a chatbot for debriefing generals?), “Fury’s” test flight signals not just a technical milestone, but a policy pivot: toward modular, scalable, and ethically programmed air defense. Whether these scalable CCAs will one day be quoted alongside crude futures is anyone’s guess, but one thing’s clear—this drone today, gone tomorrow approach is the very model of a modern major milestone.

The Sources

by Vista Partners LLC November 11, 2025

The American Partnership for Eosinophilic Disorders Rolls Out a Coast-to-Coast Campaign; Eupraxia Pharmaceuticals Earns Spotlight in the Race Against EoE -( $EPRX $XBI $IBB )

For most commuters hustling through Boston’s MBTA tunnels, Chicago’s labyrinthine corridors, or the glassy speedways of Orlando’s Brightline, digestive worries might seem like yesterday’s lunch. Yet, November 2025 finds a new contender vying for attention amid the ads for luxury watches and obscure real estate ventures—the American Partnership for Eosinophilic Disorders (APFED) has rolled out its national “EoE Awareness on the Move” campaign, doubling down on the idea that visibility isn’t just for billboards.

With witty, pointed public service messages (“If swallowing feels like rush hour traffic, it might be EoE”) plastered across transit hubs, APFED’s effort has transformed everyday commutes into teachable moments for a disease that’s long preferred to linger in obscurity. Eosinophilic esophagitis (EoE), an immune-mediated condition where white blood cells euphemistically known as “eosinophils” throw unwelcome parties in the esophagus, often causes chronic inflammation. This subversive cell build-up can lead to scarring, narrowing, and the sort of swallowing difficulties that make every bite a gamble worthy of Las Vegas. In severe bouts, food impaction leaves some patients feeling as if half their dinner is stuck on the morning commute.

Why Early Recognition Matters

Despite growing recognition among specialists, diagnosis of EoE historically takes years longer than it might for more “fashionable” ailments—a lag APFED aims to close with a combination of public outreach and clinical advocacy. Most cases are triggered by innocuous-seeming dietary culprits, or, for the unlucky, environmental allergens. And while there’s no magic pill for a permanent cure, timely intervention can prevent the esophagus from resembling a badly maintained subway tunnel—full of blockages and detours.

Biotech’s Newest Hopeful

Fresh momentum comes courtesy of the biotech circuit, where Eupraxia Pharmaceuticals (NASDAQ: EPRX) has managed to rouse more than a few market watchers from their usual mid-morning ennui. The company’s investigational therapy for EoE, which recently cleared a key clinical milestone, addresses the stubborn inflammation head-on. Eupraxia’s candidate is designed to reduce the population of troublesome eosinophils, potentially offering relief without the side effects of chronic steroid use—a development some analysts have described as “the closest thing to a Starbucks on every block for EoE patients”. Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We believe the prolonged duration of symptom response that we are seeing with EP-104GI is truly a unique clinical result and will potentially provide a once-a-year therapy to patients with EoE. And overall, we continue to see that the more drug we deliver to the tissues, the better the results. Independent market research has shown that the majority of patients with EoE undergo a routine endoscopy at least once a year to monitor the progress of their disease, which is also consistent with national guidelines. Based on this, leading KOLs in EoE see a potential treatment regimen where EP-104GI is administered during this routine annual procedure, in contrast to current standards of care which are inconvenient and involve swallowing oral steroids daily or injecting themselves weekly with a biologic. As a result, we believe EP-104GI has the potential to significantly enhance the current standard of care for patients with EoE. We look forward to reporting additional 12-month data from a larger patient set later this year.”

Analysts also believe that if the therapy continues its current trajectory, FDA interest is likely to accelerate, possibly leading to broader adoption in the near-to-medium term. Patient communities, for their part, are watching results with the kind of anticipation usually reserved for playoff sports or Black Friday deals—proof that even in medicine, hope can be contagious.

The Takeaway

As APFED’s campaign transforms America’s transportation arteries into corridors of awareness, and Eupraxia Pharmaceuticals (NASDAQ: EPRX) sprints toward what could be a breakthrough treatment, the message is clear: For EoE sufferers, diagnosis and options are moving steadily from the shadows to the center of the stage. Commuters might still grumble about delays, but for those facing the daily challenge of EoE, just getting the message through might be the journey that matters most.

by Vista Partners LLC November 11, 2025

Rare Earth Elements: How Ramaco and M2i Global Aim to End U.S. Reliance on China -( $METC $MTWO )

The recent groundbreaking at Wyoming’s Brook Mine marks a seismic shift in America’s approach to securing vital raw materials for defense and technology, as Ramaco Resources (METC) launched the first new U.S. rare earth element (REE) mine in over 70 years. This move—propelled by growing supply chain concerns and the strategic urgency to reduce dependence on China—signals a new era of American mineral independence.

Wyoming’s Brook Mine: A Game Changer

Ramaco Resources’ Brook Mine is more than just a new operation; it is a national milestone. The deposit, located in soft, shallow carbonaceous ore, spans over 15,800 acres and contains six of the 17 rare earth elements critical to both U.S. industry and national security—scandium, gallium, germanium, and others. Industry analysts estimate the mine could supply domestic needs for more than a century, with initial output set to serve U.S. technology and military customers. The Brook Mine’s unique geology—a trove embedded in coal rather than traditional hard rock—has also ignited fresh optimism about the scalability and environmental impact of rare earth extraction in North America.

Shifting the Balance: Competition With China

For decades, the U.S. remained reliant on China, which currently dominates more than 70% of global rare earth mineral supply, refining 91% of REEs and producing 94% of REE-based magnets. Chinese export restrictions in 2025—most notably a rare earth embargo in retaliation for U.S. tariffs—exposed the acute vulnerability in the American manufacturing and defense supply chain. With Brook Mine operational, Ramaco’s vertically integrated model (from mining to on-site processing and domestic sales) seeks to help fill the gap and fortify domestic resilience.

M2i Global: A Strategic Force in Critical Minerals

M2i Global (MTWO) has emerged as a pivotal partner in the U.S. critical minerals race, leveraging advanced technology, research, and public-private partnerships to reshape how the nation sources, secures, and manages these resources. The company is developing America’s first Critical Mineral Reserve, a public-private initiative based at the Hawthorne Army Depot in Nevada, designed to stockpile, refine, and distribute crucial minerals for defense and clean energy production. M2i’s approach blends direct mining, cutting-edge recycling, and mine remediation to extract minerals not only from new deposits but also from waste and legacy mine sites—making U.S. supply chains more robust and environmentally responsible.

Through strategic partnerships with both domestic and international players—including Lion Crest in Australia and organizations like Not For Sale to ensure ethical sourcing—M2i Global works to align their initiatives with federal agencies such as the Department of Defense. The company’s recycling initiatives and supply chain innovations enhance mineral independence and readiness, particularly for defense applications and advanced clean technologies.

The Road Ahead: America’s Mineral Independence

As Wyoming’s Brook Mine begins production and M2i Global (MTWO) accelerates its first of its kind Critical Mineral Reserve, the U.S. is taking long-overdue steps to ensure that its manufacturing, tech, and defense sectors are not beholden to foreign supply disruptions. Backed by new federal policies and industry investment, these efforts not only increase domestic stockpiles but also set new environmental and ethical standards for mineral procurement. America’s critical minerals race has entered a new phase—with actors like Ramaco Resources and M2i Global at the forefront of a domestic industrial revival.

The Sources

by Vista Partners LLC November 11, 2025

BigBear.ai Delivers Q3 Revenue Beat and Announces $250M Ask Sage Acquisition to Strengthen Government AI -( $BBAI $SPY $NVDA )

BigBear.ai (BBAI) strutted through the third quarter of 2025 with the confidence of a bear on Wall Street, announcing numbers that—while down from last year—showed enough resilience to keep investors upbeat and slightly bemused. The AI defense contractor reported revenue of $33.1 million, a 20% drop from its 2024 tally, causing some to wonder if fewer robots were being deployed, or just that Army contracts were running light on batteries this season. Despite this, BigBear.ai managed to deliver an earnings-per-share surprise, posting -$0.03, beating analyst predictions of -$0.05. It’s the kind of win that, if you blink, you might miss, but Wall Street surely didn’t—shares promptly jumped 14%, proving that even a small AI beat can rouse the algorithm-friendly bulls from their slumber.

Acquisition: Ask Sage Joins the Bear Den

This quarter’s highlight was BigBear.ai’s $250 million acquisition of Ask Sage, a generative AI platform best known for keeping sensitive government and defense data safer than grandma’s secret apple pie recipe. The move, according to the company, is meant to “strengthen secure deployment of agentic systems” across highly regulated sectors—which, in layman’s terms, means keeping both the Pentagon and the accountants happy. Critics might suggest that BigBear.ai is collecting AI startups the way billionaire hobbyists collect yachts, but management insists it’s all part of a disciplined strategy to “address growing demands among government and regulated industry clients for compliant artificial intelligence”. If AI really is the new gold rush, BigBear.ai is clearly determined to stake its claim—while hiring a robot sheriff to keep prospectors honest.

Cash, Contracts, and Margin Management

BigBear.ai ended the quarter with a record $456.6 million in cash and, for dramatic effect, no debt whatsoever. This left management with an enviable flexibility to pick up more AI startups, fend off competition, or simply admire their cash pile while sipping coffee brewed by an algorithm. The company’s gross margin came in at 22%, down from prior years, but enough to fund further research into why profit margins seem inversely correlated with executive optimism. Meanwhile, recent wins in government contracting—particularly with the U.S. Army—continue to form the backbone of BigBear.ai’s strategy, proving that, in Washington, a bear can still get fat by bidding on the right projects.

The Street’s Verdict: Grr… but Not Growling

While Wall Street lauded the earnings beat and strategic moves, some analysts remain cautious, noting the company’s ongoing operating losses—$21.9 million this quarter, up from $10.5 million a year ago. Still, with shares roaring back, BigBear.ai’s ability to generate positive sentiment (not to mention the occasional positive net income) may set the tone for AI-centric defense stocks going into 2026. Investors who remember the last time a software company acquired an “emerging platform” are keeping their champagne on ice, just in case this bear turns out to be a raging bull in disguise.

In a sector where tomorrow’s headline can be written by yesterday’s algorithm, BigBear.ai continues to juggle innovation, acquisition, and government contracts with the nimbleness of an AI-coached circus bear. If they manage to keep those balls in the air, shareholders may yet get the last laugh.

The Sources…

by Vista Partners LLC November 11, 2025

Honoring Service, Holding Perspective: Veterans Day 2025 in Reflection

By any measure, America’s national calendar has its serious days. Memorial Day arrives with the scent of barbecue and the solemn echo of taps. Independence Day stands loud and proud, strewn in fireworks and sentiment. But Veterans Day—marked this year with a brisk November morning and the familiar hum of small-town parades—is the country’s quiet professional: steady, dignified, and ever on duty.

Officially observed every November 11, the holiday’s roots trace to the armistice that silenced World War I’s guns in 1918, at precisely the eleventh hour of the eleventh day of the eleventh month. Originally “Armistice Day,” it was rededicated by Congress in 1954 to honor all who served, not just those who fought in the Great War—an expansion that would have earned nods from accountants of efficiency: one day, one nation, all services included.

The occasion carries a distinctly American flavor of gratitude blended with pragmatism. Local diners offer free coffee to veterans. Lawmakers deliver speeches that reference sacrifice and democracy in careful proportion. Meanwhile, on Wall Street, markets pause for a moment of reflection before moving briskly back to debating interest rates and earnings reports—a reminder, perhaps, that stability, too, is a dividend of service.

Yet amid the parades and patriotism, the day’s meaning persists not in grand gestures but in the everyday moments it quietly authorizes: a neighbor’s handshake, a child’s question about a folded flag, an old veteran straightening his cap as the high school band passes by. For some, that’s all the ceremony needed.

A century and change after the first armistice, America remains a country that occasionally forgets how young it is, and how much of its story was written by those willing to serve rather than speak. Veterans Day endures as a nudge to remember—not just the victories, but the vigilance that secures the peace between them.

If the holiday had a voice, it might sound like the old sergeant at the VFW hall: humble, practical, maybe cracking a dry joke between toasts—but always reminding everyone that freedom’s paperwork never quite files itself.

by Vista Partners LLC November 11, 2025

Lovable’s AI Surge: How the Swedish Startup Blitzed to 8 Million Users (and Investor Euphoria) -( $META $NVDA $GOOG )

Lovable, the Stockholm-based AI coding platform, is making headlines after closing in on eight million users and securing a remarkable $228 million in funding—surely enough pocket change to keep the espresso machines humming for every developer north of Berlin. In a market where startups regularly emerge and vanish faster than a TikTok trend, Lovable’s meteoric ascent has left Silicon Valley’s elite clutching their monocles in surprise.

Startup Growth That Defies Gravity

Founded barely a year ago, Lovable now boasts a runaway user tally, up from just 2.3 million in July to nearly eight million by November—a jump steep enough to make most SaaS founders hope the seatbelts are properly fastened. Each day, 100,000 new products are reportedly built using Lovable’s platform, which invites anyone to become a “vibe coder”—no actual coding prerequisite required. For those keeping score at home, that’s about one new app every 0.8 seconds. Even the most caffeinated engineers might struggle to keep pace.

Funding Finesse and Investor FOMO

After announcing a $200 million raise at a $1.8 billion valuation this summer—led by Accel and not, as previously rumored, by a benevolent Swedish prince—Lovable finds itself beset by unsolicited offers from investors hoping to catch a ride before the rocket reaches a rumored $5 billion valuation. CEO Anton Osika insists the company is “not capital constrained,” leaving analysts to wonder if Lovable plans to buy a controlling share in the Scandinavian furniture market just for sport.

The Vibe Coding Boom—and the Sighs of Caution

This explosion of “vibe coding”—apps generated from simple English prompts—is changing the software development landscape. Even Fortune 500 companies have joined the party, hoping Lovable can supercharge their teams’ creativity without the messy side effects of caffeine withdrawal or code review fatigue. Still, research from Barclays suggests that site traffic to Lovable and its peers peaked months ago before slipping back by around 40%. Is “vibe coding” a revolution, or just a particularly groovy phase before everyone remembers they do, in fact, need programmers?.

Competitors and the Fight for Relevance

Lovable’s model faces serious competition: Replit, StackBlitz, OpenAI’s latest playground, and Google’s Firebase Studio all want a piece of this market, and none are shy about deploying AI to make app development less cryptic than a teenager’s text messages. In recognition of these shifting sands, even established tech giants are recalibrating their hiring practices, with some laying off junior coders as AI-generated code grabs the spotlight.

What’s Next For Lovable?

Lovable’s next steps remain deliciously vague—Osika isn’t sharing new revenue details, perhaps preferring to preserve an air of mystery worthy of a Nordic detective series. But with a user base blitzing past eight million and the investment world in a collective swoon, Lovable’s story looks set to continue at breakneck speed. The only question remaining: when the next big lull hits, will anyone remember how to write a for-loop by hand? As Lovable reassures investors and developers, the answer—much like its code—remains beautifully, playfully, open to interpretation.

The Sources…

by Vista Partners LLC November 10, 2025

Stocks Soar With Shutdown Relief Outlook Surfaces On Monday -( $AVGO $EPRX $INTG $LLY $NOK $NVDA $OPEN $PLTR $RIO $SER $SPY $TSLA Rise!)

Stocks soared Monday, November 10, 2025, with a rally that could make even the most seasoned bear consider a hibernation sabbatical. Wall Street’s major indexes leapt as Congress inched closer to ending the record-breaking government shutdown, unleashing the kind of risk-on mood that calls for celebratory confetti—preferably recycled from last week’s shredded retail reports. Also, with AI stocks soaring today, the government dusting off its economic calculators, and the gold bugs dancing, Monday offered market watchers just enough drama to make the wait for delayed data seem almost entertaining. Investors can only hope Congress keeps the shutdowns as rare as a unicorn sighting—and leaves the market fireworks to Wall Street.

Index Performances

S&P 500 climbed 103.63 points, or 1.54%, to 6,832.43, led by consumer and tech titans flexing post-shutdown optimism.
Dow Jones Industrial Average gained 381.53 points, or 0.81%, closing at 47,368.63, with airlines and restaurant giants feasting on stimulus rumors like it’s Thanksgiving early.
Nasdaq Composite roared 522.64 points higher, rising 2.27% to finish at 23,527.17, thanks to AI and chip stocks leading a comeback worthy of a Silicon Valley reboot.
Russell 2000 index advanced 22.82 points, or 0.94%, to 2,455.65, with small caps playing catch-up as risk appetite returned.

Macroeconomic and Fed Reports

Monday delivered little in the way of fresh macro data—thanks, government shutdown!—but optimism is high for a bevy of backlogged reports to follow once the lights are on at the Bureau of Labor Statistics. The latest ADP private payrolls showed a solid 42,000 increase for October, keeping interest rate cut hopes alive, while the September jobs report (finally!) is expected to arrive imminently.

Treasury yields rose, with the 10-year closing at about 4.121%, the 2-yr at 3.601%, and market watchers now pencil in nearly a 60% chance of a Fed rate cut next month. FOMC’s next scheduled rate decision comes in December, and the bond market seems determined to front-run the Fed’s dovish pivot. Tariff news was equally dramatic: Supreme Court justices expressed skepticism over the legal basis for Trump-era Section 301/IEEPA tariffs, suggesting possible refunds of $130-$140 billion—though fiscal impact is expected to be modest.

Commodities and Crypto

Gold hit a two-week high, trading above $4,123.40 per ounce as traders priced in reopening hopes and more dovish Fed action.
Silver rallied to50.405 per ounce.
Crude oil bounced but remained rangebound amid broader commodity volatility closing at $60.05/bbl.
Bitcoin rebounded ~1.79% to $105,890, with bullish sentiment returning after a surprise dip below $100,000 last week and traders pining for a year-end run toward $150,000.

Corporate News and Stock Highlights

Eli Lilly (LLY) surged 4.8% to a record $969.14 after an analyst upgrade and a landmark Medicare pricing deal for GLP-1 drugs, cementing its place atop the obesity and diabetes therapeutics mountain.
NVIDIA (NVDA) jumped ~5%, leading the AI rebound and riding momentum into tomorrow’s catalyst-heavy earnings and partnership news with OpenAI—a pivotal week for the chip champ.
Apple (AAPL), Meta (META), Broadcom (AVGO), and Tesla (TSLA) joined the “Magnificent Seven” revival. Tesla rose 3.6% despite executive exits and China sales hitting a three-year low—fear not, Elon’s drama remains bullish for volatility traders. Meta secured a rating upgrade, despite being the year’s “Magnificent Seven” doormat after a bout of aggressive AI spending; cue the Mark Zuckerberg meme parade.
Palantir Technologies (PLTR) led S&P gainers, up 8.81% as investors bet on its government and White House ties, data contracts, and bold AI ambitions.
Broadcom (AVGO, +2.56%) basked in bullish analyst target hikes fueled by its OpenAI partnership for custom AI chips.
OKLO (OKLO) slipped 1% amid investor jitters, pending an earnings call tomorrow, but made headlines with a $2 billion nuclear fuel partnership and remains up 425.29% YTD.
Opendoor (OPEN, $7.97, +21.49%), Nokia (NOK, +1.90%), McDonald’s (MCD, -.19%), Rio Tinto (RIO, $70.29, +1.38%, Oracle (ORCL, +.66%), and Intel (INTC, +.84%) saw mixed action, with Nokia riding 5G expansion news in Latin America, Oracle weathering insider selling, and McDonald’s surfing alongside broader consumer and restaurant sector strength

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.5095)), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.23, +14.84%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.5008), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR, $1.47, +5%) and M2i Global, Inc. (MTWO) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.99, +2.05%) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $36.88, +1.60%) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

by Vista Partners LLC November 10, 2025

Navitas Semiconductor’s $100M Raise: Powering the Next Wave of AI Chips -( $NVTS $SPY )

Navitas Semiconductor (NVTS, $9.58, +22.19% currently on Monday) turned up the voltage on Wall Street’s risk tolerance last week, announcing a $100 million private placement that, if nothing else, once again proves the semiconductor crowd is not afraid to mix science with spectacle. The Torrance, California–based power IC specialist, best known for gallium nitride (GaN) and silicon carbide (SiC) wizardry, sealed the deal to sell nearly 14.8 million shares of Class A stock at $6.75 per share—a discount that would make even a discount retailer blush, especially as shares wobbled at $8.84 midweek after a head-spinning 34% slide following a previous 352% meteor ride.

Financing the Big “Navitas 2.0” Dream

The company candidly describes the capital raise as rocket fuel for “Navitas 2.0,” a strategic U-turn targeting the sorts of high-power markets you’d expect from a tech firm with vaulting ambitions and a taste for next-gen acronyms: AI data centers, grid infrastructure, and industrial electrification all get billing in the new manifesto. CEO Chris Allexandre, never one for understatement, cited the need to “accelerate our momentum into higher-power markets,” adding a tone of Silicon Valley bravado possibly powered by a few GaN chips of his own.

Numbers, Volatility, and the Margins

On the numbers front, Navitas is brandishing a current ratio close to 8—a financial buffer beefy enough to handle an R&D lab explosion or, more likely, to maintain expansion as it pivots away from low-margin consumer gadgets toward high-wattage grid and AI applications. It’s a necessary shift, as Q3 saw mobile and consumer sales—a sector described by one analyst as “the grownup’s equivalent of selling lemonade at a loss”—down 53% year over year. The $100 million is believed to boost high-voltage R&D, expand production for industrial modules, and help the firm recover from a shareholder hangover triggered by a recent tumble (because nothing says “new era” like issuing a pile of new shares to old investors who just saw their stakes diluted).

Strategic Partners and Industry Positioning

Navitas’ expansion plan is not entirely “Field of Dreams”–grade optimism; the company is quietly aligning with power players like NVIDIA, selling modules that hope to power AI barns and keep data centers sucking up electrons with greater efficiency. Holding a stash of over 300 patents and boasting a “world’s first CarbonNeutral-certified semiconductor” label, it stands as the rare chip company that tries to balance wattage with wokeness.

The Sum…

For now, investors face a classic Wall Street conundrum: Can the company’s high-voltage pitch outpace its habit of net losses, or will it all short-circuit before the next round of fundraising? With ~$150.6 million in the cash drawer and analysts projecting gross margins ticking up as consumer contracts phase out, at the very least, Navitas has bought itself another season in the big leagues.

After all, if the passage to “Navitas 2.0” demands cash, charisma, and a thick-skinned investor base, at least one of those currencies has just been substantially replenished.

The Sources

by Vista Partners LLC November 10, 2025

Biotech Market Movers: Cogent Biosciences and GeoVax Labs Unveil Clinical Wins and Vaccine Innovation -( $COGT $GOVX $IBB $XBI )

Cogent Biosciences (COGT) and GeoVax Labs (GOVX) offered investors and clinicians fresh cause for cautious celebration this week, both releasing data-laden news that—if not quite cocktail-hour material—could at least liven up a Monday earnings call with a smidgen of biotech bravado.

Cogent Biosciences: The Tumor Tango

Cogent Biosciences waltzed onto the market stage with positive Phase 3 results for its bezuclastinib-sunitinib duet in second-line gastrointestinal stromal tumors (GIST). In true headline-making fashion, Cogent’s trial didn’t just move the needle—it demanded a spotlight. Patients prescribed the drug combo, presumably with equal measures of hope and trepidation, saw median progression-free survival double to 16.5 months versus 9.2 months for those on sunitinib alone. Objective response rates were just as dazzling—46% for the duo versus 26% for the solo act, giving statisticians and bullish shareholders simultaneous palpitations, the good kind.

With Wall Street’s favorite narrative arc—namely, “disruptive innovation” plus “share price fireworks”—Cogent CEO Andrew Robbins declared the results “historic,” a sentiment usually reserved for spacecraft landings, not Phase 3 trial readouts. Wall Street rallied accordingly, sending shares higher with the kind of exuberance not seen since caffeine futures rallied after the last inflation print.

GeoVax & World Immunization Day

GeoVax Labs took a different tack, recognizing World Immunization Day by spotlighting its work on next-generation multi-antigen COVID vaccines. The company took pains to note its approach doesn’t just chase the prevailing variant du jour—it aims to offer enduring protection, particularly for immunocompromised individuals who, one suspects, would prefer their antibodies served in robust, multi-antigen cocktails anyway.

CEO David Dodd shared recent safety and efficacy data, underlining that trial subjects suffered no serious vaccine-related adverse events—a clinical outcome so rare. GeoVax’s safety profile overall suggests the biotech might soon be elevating standard COVID protection beyond “good enough,” much to the relief of most trial-weary epidemiologists.

Market Wisdom: Optimism on Tap

While markets rarely hand out “feel-good” days to the biotech sector, Cogent and GeoVax demonstrated that sometimes two press releases really can make Monday look a little less like a repeat episode and a little more like a pilot for the next big hit. Cogent eyes a first-half 2026 FDA submission, while GeoVax tempts investors with the prospect of next-level vaccines, reminding us that optimism—not just good data—remains the day trader’s favorite superpower.

The Sources

by Vista Partners LLC November 10, 2025

Former Lilly Leaders Launch 501 Ventures to Drive Next-Gen Obesity, Diabetes, & Metabolic Breakthroughs – ( $AZN $LLY $NVO $MTSR $MODD )

Two veterans of Eli Lilly’s diabetes business have a fresh diagnosis for the biotech world: more science, less ceremony. Enrique Conterno and Meg Powell, former senior leaders at Lilly, have teamed up to launch 501 Ventures, a new venture capital firm devoted to “advancing the science” of metabolic health.

The duo is betting that the GLP-1 era—driven by blockbusters such as Lilly’s Mounjaro and Novo Nordisk’s (NVO) Wegovy—is merely the first act in a far longer performance. “Some people think the metabolic health story has been written,” Conterno said during an interview at this year’s ObesityWeek conference in Atlanta. “It’s still going to be written.”

From Big Pharma to Venture Capital

Conterno, who led Lilly Diabetes and Lilly USA before serving as CEO of FibroGen, now chairs 501 Ventures while also sitting on Zealand Pharma’s board. Powell, also a Lilly alum, later held roles at GSK, Aerial BioPharma, and Target PharmaSolutions. Together, they bring both commercial know-how and scientific insight to the firm.

Their partnership comes with a playful twist. The firm’s name—501 Ventures—pays homage to U.S. Route 501, the road connecting Duke University and the University of North Carolina at Chapel Hill. Conterno, a Duke graduate, and Powell, a proud Tar Heel, admit their school rivalry still colors their collaboration. “We have a bit of a rivalry,” Conterno joked.

Betting on Early-Stage Science

The 501 team plans to invest primarily in early-stage biotech startups developing next-generation medicines for obesity and metabolic health. Target projects are those a few years from the clinic—programs that need both capital and guidance to determine if they truly stand apart.

Powell says the firm’s mission is to keep investments focused on data rather than bureaucracy. “As soon as you figure out that they’re not best-in-class, shelve them,” she said, emphasizing a disciplined and scientific approach over investor hype.

While the firm has not disclosed its fundraising figures, Powell noted that 501 Ventures is engaging with biopharma companies eager for a front-row seat to emerging science. “So much of what happens in biotech fundraising goes to overhead instead of doing the science,” she said. “We’re committed to fixing that.”

The Global Hunt for Innovation

Conterno and Powell plan a global search for promising research hubs. They cited Boston, San Francisco, San Diego, Shanghai, Tokyo, and Copenhagen as key regions of focus, with Indianapolis receiving an honorable mention thanks to their shared Lilly heritage.

Beyond new drugs, the metabolic health ecosystem continues to evolve through device innovation. Modular Medical (MODD), a California-based medtech company, is making progress with its Pivot Insulin Delivery System—a simplified, next-generation insulin patch pump designed to eliminate many of the usability barriers of traditional pumps. The company recently announced progress toward FDA clearance and a manufacturing ramp-up to support anticipated commercialization. Its goal is to make insulin delivery easier and more affordable for people with diabetes, complementing the pharmaceutical advances that 501 Ventures aims to accelerate.

A Competitive Field with Many Innings to Play

The obesity and metabolic sectors are seeing renewed dealmaking activity. Pfizer recently edged out Novo Nordisk to acquire Metsera (MTSR), while AstraZeneca (AZN) exercised its option to buy SixPeaks Bio—both signaling that big pharma remains firmly in the hunt for differentiation.

Still, Conterno sees the opportunity set as just beginning. “We’ve only played the first few,” he said. “I don’t know if it’ll go to 18 innings like in the World Series, but there’s a lot of innings left to play.”

For now, 501 Ventures looks poised to step to the plate—armed with insider experience, a friendly rivalry, and a mission to fund ideas that could reshape the future of metabolic health.

All Posts

Jet-Powered Disruption

Mass Production with American Flair

Wingmen Wanted: The Broader CCA Race

AI Morality: Smarter Than Your Average Landmine

Closing Thoughts

The Sources

Why Early Recognition Matters

Biotech’s Newest Hopeful

The Takeaway

Wyoming’s Brook Mine: A Game Changer

Shifting the Balance: Competition With China

M2i Global: A Strategic Force in Critical Minerals

The Road Ahead: America’s Mineral Independence

The Sources

Acquisition: Ask Sage Joins the Bear Den

Cash, Contracts, and Margin Management

The Street’s Verdict: Grr… but Not Growling

The Sources…

Startup Growth That Defies Gravity

Funding Finesse and Investor FOMO

The Vibe Coding Boom—and the Sighs of Caution

Competitors and the Fight for Relevance

What’s Next For Lovable?

The Sources…

Index Performances

Macroeconomic and Fed Reports

Commodities and Crypto

Corporate News and Stock Highlights

VP Watchlist Updates

The Sources

Financing the Big “Navitas 2.0” Dream

Numbers, Volatility, and the Margins

Strategic Partners and Industry Positioning

The Sum…

The Sources

Cogent Biosciences: The Tumor Tango

GeoVax & World Immunization Day

Market Wisdom: Optimism on Tap

The Sources

From Big Pharma to Venture Capital

Betting on Early-Stage Science

The Global Hunt for Innovation

A Competitive Field with Many Innings to Play

The Sources

Your Guide To Staying Informed In The Markets